Deep Brain Stimulation (DBS) is an FDA-approved procedure, a two-part surgery that involves implanting a device that sends ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

The next episode of “Baylen Out Loud” is called “You Don’t Have to Stare Into My Soul.” “Baylen Out Loud” airs at 9 p.m.

Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center have been recognized by the ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...